Index - P/E - EPS (ttm) - Insider Own 51.42% Shs Outstand 17.58M Perf Week 25.10%
Market Cap 302.65M Forward P/E - EPS next Y - Insider Trans 110.09% Shs Float 11.80M Perf Month 23.73%
Income - PEG - EPS next Q -0.83 Inst Own 41.37% Short Float 0.43% Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio 0.40 Perf Half Y -
Book/sh -234.70 P/B - EPS next Y - ROA - Short Interest 0.05M Perf Year -
Cash/sh 1.92 P/C 6.50 EPS next 5Y - ROE - 52W Range 9.71 - 16.00 Perf YTD 3.83%
Dividend Est. - P/FCF - EPS past 5Y -63.82% ROI - 52W High -22.12% Beta -
Dividend TTM - Quick Ratio 4.59 Sales past 5Y 181.38% Gross Margin - 52W Low 28.32% ATR (14) 0.93
Dividend Ex-Date - Current Ratio 4.59 EPS Y/Y TTM - Oper. Margin - RSI (14) 60.34 Volatility 11.07% 8.06%
Employees 77 Debt/Eq 0.62 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 21.25
Option/Short No / Yes LT Debt/Eq 0.47 EPS Q/Q -3282.42% Payout - Rel Volume 22.45 Prev Close 11.73
Sales Surprise -100.00% EPS Surprise -1579.39% Sales Q/Q -100.00% Earnings Aug 29 AMC Avg Volume 128.41K Price 12.46
SMA20 12.30% SMA50 10.69% SMA200 10.69% Trades
Volume 2,882,646 Change 6.22%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-13-24 Initiated Wedbush
Outperform
$18
Aug-13-24 Initiated TD Cowen
Buy
Aug-13-24 Initiated Needham
Buy
$23
Aug-13-24 Initiated Jefferies
Buy
$21
Aug-13-24 Initiated Cantor Fitzgerald
Overweight
$23
Sep-10-24 04:05PM
Aug-29-24 04:05PM
Jul-18-24 07:08PM
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RA CAPITAL MANAGEMENT, L.P. Director Jul 22 '24 Buy 12.00 8,333,333 99,999,996 8,693,579 Jul 24 04:27 PM 5AM Partners VI, LLC 10% Owner Jul 22 '24 Buy 12.00 833,333 9,999,996 1,182,054 Jul 24 04:15 PM venBio Global Strategic Fund I 10% Owner Jul 22 '24 Buy 12.00 416,666 4,999,992 1,936,637 Jul 22 08:26 PM GC Corp. 10% Owner Jul 22 '24 Buy 12.00 1,666,666 19,999,992 3,306,900 Jul 22 08:25 PM GC Corp. 10% Owner Jul 22 '24 Buy 12.00 416,666 4,999,992 1,260,512 Jul 22 08:25 PM Huh Yong-Jun Director Jul 22 '24 Buy 12.00 2,083,332 24,999,984 3,306,900 Jul 22 08:22 PM
Index RUT P/E - EPS (ttm) -1.93 Insider Own 38.86% Shs Outstand 41.29M Perf Week 3.90%
Market Cap 1.10B Forward P/E - EPS next Y -2.47 Insider Trans -12.16% Shs Float 28.88M Perf Month -2.03%
Income -82.83M PEG - EPS next Q -0.51 Inst Own 70.09% Short Float 18.51% Perf Quarter 8.16%
Sales 0.00M P/S - EPS this Y 3.34% Inst Trans -9.15% Short Ratio 21.40 Perf Half Y 28.41%
Book/sh 6.46 P/B 3.59 EPS next Y -27.28% ROA -26.91% Short Interest 5.35M Perf Year 71.78%
Cash/sh 6.61 P/C 3.51 EPS next 5Y - ROE -28.37% 52W Range 9.80 - 27.67 Perf YTD 67.56%
Dividend Est. - P/FCF - EPS past 5Y 5.16% ROI -27.16% 52W High -16.20% Beta 1.08
Dividend TTM - Quick Ratio 14.39 Sales past 5Y 0.00% Gross Margin - 52W Low 136.63% ATR (14) 1.25
Dividend Ex-Date - Current Ratio 14.39 EPS Y/Y TTM -164.59% Oper. Margin 0.00% RSI (14) 54.62 Volatility 5.99% 4.93%
Employees 46 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.17 Target Price 35.60
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -1.67% Payout - Rel Volume 2.99 Prev Close 23.07
Sales Surprise - EPS Surprise 25.45% Sales Q/Q - Earnings Aug 13 AMC Avg Volume 249.80K Price 23.19
SMA20 3.56% SMA50 0.26% SMA200 21.72% Trades
Volume 747,384 Change 0.52%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-09-24 Initiated H.C. Wainwright
Buy
$37
Jun-11-24 Initiated Robert W. Baird
Outperform
$32
Apr-09-24 Initiated Mizuho
Buy
$34
Mar-29-23 Initiated Jefferies
Buy
$27
Sep-18-24 04:05PM
Sep-09-24 02:05PM
Sep-04-24 09:55AM
Aug-16-24 09:55AM
Aug-13-24 04:05PM
04:05PM
Loading…
May-29-24 04:05PM
(GlobeNewswire) -8.14%
+5.67%
May-20-24 05:06PM
May-14-24 10:54PM
05:01PM
04:05PM
Apr-19-24 03:03PM
Apr-11-24 03:44PM
07:55AM
Apr-09-24 04:05PM
Mar-28-24 04:05PM
(GlobeNewswire) -5.58%
+7.45%
01:51AM
Loading…
Mar-23-24 01:51AM
Mar-19-24 08:30AM
Mar-14-24 09:53PM
04:05PM
Feb-27-24 04:05PM
Jan-03-24 09:01AM
Nov-09-23 04:05PM
Aug-17-23 06:40AM
Aug-10-23 04:05PM
May-31-23 04:55PM
May-11-23 04:05PM
Mar-24-23 06:30AM
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Heyman Richard A. Director Sep 16 '24 Sale 22.41 1,270 28,458 129,103 Sep 18 04:17 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Aug 29 '24 Sale 22.49 12,000 269,841 1,077,936 Sep 03 05:43 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Aug 27 '24 Option Exercise 2.48 4,250 10,540 4,250 Aug 29 06:36 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Aug 27 '24 Sale 22.54 4,250 95,782 0 Aug 29 06:36 PM Kintz Samuel PRESIDENT AND CEO Aug 26 '24 Sale 22.89 12,000 274,718 1,049,255 Aug 28 07:48 PM Heyman Richard A. Director Aug 15 '24 Sale 23.25 1,270 29,526 130,373 Aug 19 07:49 PM Kintz Samuel Member of immediate family of Aug 19 '24 Proposed Sale 23.71 30,000 711,300 Aug 19 04:32 PM Kintz Samuel Member of immediate family of Aug 19 '24 Proposed Sale 23.71 30,000 711,300 Aug 19 04:32 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Jul 31 '24 Sale 27.56 3,099 85,399 1,089,936 Aug 02 07:26 PM Kintz Samuel PRESIDENT AND CEO Jul 31 '24 Sale 27.56 2,270 62,555 1,061,255 Aug 02 07:25 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 31 '24 Option Exercise 2.48 991 2,458 991 Aug 02 07:23 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 31 '24 Sale 27.53 991 27,281 0 Aug 02 07:23 PM Heyman Richard A. Director Jul 31 '24 Sale 27.51 1,702 46,815 131,643 Aug 02 07:22 PM Heyman Richard A. Director Jul 31 '24 Sale 27.50 649 17,848 27,918 Aug 02 07:22 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Jul 29 '24 Sale 26.70 12,000 320,378 1,093,035 Jul 31 07:33 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 29 '24 Option Exercise 2.48 5,250 13,020 5,250 Jul 31 07:31 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 29 '24 Sale 26.68 5,250 140,052 0 Jul 31 07:31 PM Heyman Richard A. Director Jul 31 '24 Proposed Sale 26.13 649 16,958 Jul 31 04:57 PM Heyman Richard A. Director Jul 31 '24 Proposed Sale 26.13 5,045 131,826 Jul 31 04:31 PM Hohl Benjamin Officer Jul 31 '24 Proposed Sale 26.13 11,000 287,430 Jul 31 04:30 PM Lyssikatos Joseph P Officer Jul 31 '24 Proposed Sale 26.13 65,000 1,698,450 Jul 31 04:23 PM Kintz Samuel Officer Jul 31 '24 Proposed Sale 26.13 47,709 1,246,636 Jul 31 04:22 PM Kintz Samuel PRESIDENT AND CEO Jul 25 '24 Sale 24.92 12,000 299,073 1,063,525 Jul 29 05:39 PM Hohl Benjamin Officer Jul 29 '24 Proposed Sale 27.31 5,250 143,378 Jul 29 04:15 PM Lyssikatos Joseph P Officer Jul 29 '24 Proposed Sale 27.31 12,000 327,720 Jul 29 04:06 PM Heyman Richard A. Director Jul 15 '24 Sale 24.80 1,270 31,497 133,345 Jul 17 07:25 PM Patel Anish CHIEF OPERATING OFFICER Jul 15 '24 Sale 25.05 30,978 776,039 345,574 Jul 16 05:37 PM Patel Anish CHIEF OPERATING OFFICER Jul 12 '24 Sale 25.07 17,475 438,095 376,552 Jul 16 05:37 PM Patel Anish CHIEF OPERATING OFFICER Jul 16 '24 Sale 25.01 1,547 38,692 344,027 Jul 16 05:37 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 12 '24 Option Exercise 2.48 3,000 7,440 3,000 Jul 16 05:34 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 12 '24 Sale 25.07 3,000 75,195 0 Jul 16 05:34 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Jul 01 '24 Sale 22.89 12,000 274,736 1,105,035 Jul 03 04:31 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jun 27 '24 Option Exercise 2.48 4,250 10,540 4,250 Jul 01 08:03 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jun 27 '24 Sale 22.57 4,250 95,922 0 Jul 01 08:03 PM Kintz Samuel PRESIDENT AND CEO Jun 25 '24 Sale 21.66 12,000 259,902 1,075,525 Jun 27 04:35 PM Heyman Richard A. Director Jun 17 '24 Sale 21.48 1,270 27,278 134,615 Jun 20 07:20 PM Patel Anish CHIEF OPERATING OFFICER Jun 06 '24 Option Exercise 2.48 1,133 2,810 1,133 Jun 10 06:46 PM Patel Anish CHIEF OPERATING OFFICER Jun 06 '24 Sale 20.06 1,133 22,722 0 Jun 10 06:46 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER May 29 '24 Option Exercise 1.12 12,000 13,440 12,000 May 31 04:05 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER May 29 '24 Sale 21.73 12,000 260,800 0 May 31 04:05 PM Kintz Samuel PRESIDENT AND CEO May 28 '24 Option Exercise 1.12 12,000 13,440 12,000 May 30 05:56 PM Kintz Samuel PRESIDENT AND CEO May 28 '24 Sale 23.18 12,000 278,210 0 May 30 05:56 PM Hohl Benjamin CHIEF FINANCIAL OFFICER May 28 '24 Option Exercise 2.48 4,250 10,540 4,250 May 30 05:54 PM Hohl Benjamin CHIEF FINANCIAL OFFICER May 28 '24 Sale 23.18 4,250 98,530 0 May 30 05:54 PM Heyman Richard A. Director May 16 '24 Sale 23.74 1,270 30,150 135,885 May 20 07:46 PM Gupta Rishi Director May 16 '24 Sale 22.14 1,033,300 22,877,262 254,814 May 20 05:03 PM ORBIMED ADVISORS LLC Director May 16 '24 Sale 22.14 1,033,300 22,877,262 254,814 May 20 05:00 PM Patel Anish CHIEF OPERATING OFFICER May 14 '24 Option Exercise 2.48 1,107 2,745 1,107 May 16 07:29 PM Patel Anish CHIEF OPERATING OFFICER May 14 '24 Sale 25.00 1,107 27,675 0 May 16 07:29 PM Patel Anish CHIEF OPERATING OFFICER May 09 '24 Option Exercise 2.48 260 645 260 May 13 07:35 PM Patel Anish CHIEF OPERATING OFFICER May 09 '24 Sale 25.06 260 6,515 0 May 13 07:35 PM Patel Anish CHIEF OPERATING OFFICER May 06 '24 Option Exercise 2.48 4,875 12,090 4,875 May 08 08:40 PM Patel Anish CHIEF OPERATING OFFICER May 06 '24 Sale 22.72 4,875 110,769 0 May 08 08:40 PM Hohl Benjamin CHIEF FINANCIAL OFFICER May 03 '24 Option Exercise 2.48 1,000 2,480 1,000 May 07 06:58 PM Hohl Benjamin CHIEF FINANCIAL OFFICER May 03 '24 Sale 22.50 1,000 22,500 0 May 07 06:58 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Apr 29 '24 Option Exercise 1.12 12,000 13,440 12,000 May 01 07:04 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Apr 29 '24 Sale 17.92 12,000 214,988 0 May 01 07:04 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Apr 29 '24 Option Exercise 2.48 3,250 8,060 3,250 May 01 07:02 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Apr 29 '24 Sale 16.97 3,250 55,165 0 May 01 07:02 PM Kintz Samuel PRESIDENT AND CEO Apr 25 '24 Option Exercise 1.12 12,000 13,440 12,000 Apr 29 06:50 PM Kintz Samuel PRESIDENT AND CEO Apr 25 '24 Sale 16.89 12,000 202,700 0 Apr 29 06:50 PM Patel Anish CHIEF OPERATING OFFICER Apr 11 '24 Option Exercise 2.48 14,903 36,959 17,500 Apr 15 07:06 PM Patel Anish CHIEF OPERATING OFFICER Apr 11 '24 Sale 25.03 17,500 438,098 0 Apr 15 07:06 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Apr 11 '24 Option Exercise 1.12 30,000 33,600 30,000 Apr 15 07:06 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Apr 11 '24 Sale 25.04 30,000 751,332 0 Apr 15 07:06 PM Kintz Samuel PRESIDENT AND CEO Apr 11 '24 Option Exercise 1.12 47,709 53,434 47,709 Apr 15 07:05 PM Kintz Samuel PRESIDENT AND CEO Apr 11 '24 Sale 25.04 47,709 1,194,700 0 Apr 15 07:05 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Apr 11 '24 Option Exercise 2.48 14,000 34,720 14,000 Apr 15 07:04 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Apr 11 '24 Sale 24.72 14,000 346,149 0 Apr 15 07:04 PM Heyman Richard A. Director Apr 11 '24 Sale 25.03 5,045 126,279 138 Apr 15 07:03 PM Heyman Richard A. Director Apr 15 '24 Sale 19.99 1,270 25,383 137,155 Apr 15 07:03 PM Heyman Richard A. Director Apr 11 '24 Sale 25.00 649 16,225 28,567 Apr 15 07:03 PM Collins Helen Louise CHIEF MEDICAL OFFICER Apr 11 '24 Option Exercise 2.48 20,000 49,600 20,000 Apr 15 07:02 PM Collins Helen Louise CHIEF MEDICAL OFFICER Apr 11 '24 Sale 25.07 20,000 501,478 0 Apr 15 07:02 PM Ballal Rahul D. Director Apr 11 '24 Option Exercise 13.21 53,400 705,266 75,741 Apr 12 06:23 PM Ballal Rahul D. Director Apr 10 '24 Option Exercise 12.60 13,600 171,360 35,941 Apr 12 06:23 PM Ballal Rahul D. Director Apr 11 '24 Sale 23.95 53,400 1,279,068 22,341 Apr 12 06:23 PM Ballal Rahul D. Director Apr 10 '24 Sale 21.01 13,600 285,744 22,341 Apr 12 06:23 PM Patel Anish CHIEF OPERATING OFFICER Apr 08 '24 Sale 18.60 4,875 90,687 2,597 Apr 10 08:35 PM Ballal Rahul D. Director Apr 04 '24 Option Exercise 12.60 3,485 43,911 25,826 Apr 08 08:40 PM Ballal Rahul D. Director Apr 04 '24 Sale 19.15 3,485 66,729 22,341 Apr 08 08:40 PM Ballal Rahul D. Director Apr 01 '24 Option Exercise 5.73 3,237 18,534 25,578 Apr 03 09:32 PM Ballal Rahul D. Director Apr 01 '24 Sale 19.08 3,237 61,758 22,341 Apr 03 09:32 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Apr 01 '24 Option Exercise 1.12 12,000 13,440 12,000 Apr 03 09:30 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Apr 01 '24 Sale 18.60 12,000 223,146 0 Apr 03 09:30 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Mar 27 '24 Option Exercise 2.48 3,250 8,060 3,250 Mar 29 05:59 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Mar 27 '24 Sale 18.25 3,250 59,302 0 Mar 29 05:59 PM Kintz Samuel PRESIDENT AND CEO Mar 25 '24 Option Exercise 1.12 12,000 13,440 12,000 Mar 27 05:03 PM Kintz Samuel PRESIDENT AND CEO Mar 25 '24 Sale 17.56 12,000 210,661 0 Mar 27 05:03 PM Ballal Rahul D. Director Mar 20 '24 Option Exercise 5.52 13,278 73,295 35,619 Mar 22 07:46 PM Ballal Rahul D. Director Mar 20 '24 Sale 19.16 13,278 254,462 22,341 Mar 22 07:46 PM Heyman Richard A. Director Mar 19 '24 Sale 14.50 1,270 18,419 143,470 Mar 21 06:41 PM Patel Anish CHIEF OPERATING OFFICER Mar 06 '24 Sale 15.64 4,875 76,239 7,472 Mar 08 07:52 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Feb 29 '24 Option Exercise 1.12 12,000 13,440 12,000 Mar 04 05:55 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Feb 29 '24 Sale 16.42 12,000 197,006 0 Mar 04 05:55 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Feb 27 '24 Option Exercise 2.48 3,250 8,060 3,250 Feb 29 05:27 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Feb 27 '24 Sale 16.97 3,250 55,163 0 Feb 29 05:27 PM Heyman Richard A. Director Feb 15 '24 Sale 17.42 1,270 22,117 144,740 Feb 20 07:41 PM 5AM Partners VI, LLC 10% Owner Feb 14 '24 Sale 14.90 825,000 12,292,500 635,341 Feb 16 04:15 PM Patel Anish CHIEF OPERATING OFFICER Feb 06 '24 Sale 15.11 4,875 73,658 12,347 Feb 08 08:47 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
